Article Per Year (5 Year)
p-Index From 2020 - 2025
1.683
P-Index
This Author published in this journals
All Journal BALI MEDICAL JOURNAL (BMJ) Medicina Journal Pharmaceutical Science and Application (JPSA) Jurnal Kimia (Journal of Chemistry) Jurnal Farmasi Udayana E-Jurnal Medika Udayana Media Penelitian dan Pengembangan Kesehatan Sari Pediatri Paediatrica Indonesiana Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan ISM (Intisari Sains Medis) : Jurnal Kedokteran Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Journal of Health Sciences and Medicine
Ketut Ariawati
Bagian Ilmu Kesehatan Anak Fakultas Kedokteran Universitas Udayana/Rumah Sakit Sanglah Denpasar, Bali
Biochemistry, Genetics & Molecular Biology Chemistry Decision Sciences, Operations Research & Management Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Public Health

Published : 32 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 32 Documents
Search

 1   2   3   4 
COST ANALYSIS OF PATIENTS WITH SQUAMOUS CELL CERVICAL CANCER STAGE IIB-IIIB WITH PACLITAXEL CISPLATIN CHEMOTHERAPY FROM THE SOCIETAL PERSPECTIVE Ni Kd Rintan Listiani Ekayanti; Rini Noviyani; Sagung Chandra Yowani; Ketut Ariawati; I Nyoman G. Budiana
Journal Pharmaceutical Science and Application Vol 5 No 1 (2023): Journal Pharmaceutical Science and Application (JPSA)
Publisher : Departement of Pharmacy, Faculty of Mathematic and Natural Science, Udayana University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24843/JPSA.2023.v05.i01.p05

Abstract

Background: The high prevalence of cervical cancer patients and the variety of necessary expenses needed causing financial hardship to both the patient and hospital. Furthermore, the disparity between the INA-CBGs rates and the costs of treatment incurred by hospitals and the limited information regarding the costs of cervical cancer undergoing cisplatin paclitaxel chemotherapy as viewed from a societal perspective were the reasons to conduct this research. Objective: The aim of this study was to determine the cost of squamous cell cervical cancer patients at stage IIB-IIB who received cisplatin paclitaxel chemotherapy from a social perspective. So in this study the difference in costs is used to calculate costs from a hospital perspective. Methods: This research was an observational study with a prospective incidence approach and consecutive sampling as the sampling method. This research was conducted from January to June 2017 at Sanglah General Hospital, Denpasar. Cost data from a societal perspective for six chemotherapy series were obtained from the Claim Guarantee Installation, Fund Mobility Section, interviews and filling in the logbook by patients and then calculated using the micro-costing method. Results: The results of this study obtained five patients who met the inclusion criteria. From the perspective of BPJS Kesehatan, the average cost of cervical cancer with paclitaxel cisplatin chemotherapy was IDR 24.703.470,00. From a hospital perspective, the average cost of cervical cancer with paclitaxel cisplatin chemotherapy was IDR 6.619.204,00., and from the perspective of patients and their families, the average burden of costs for cervical cancer with paclitaxel cisplatin chemotherapy was IDR 9.149.300,00. Conclusion: Cost analysis on five squamous cell cervical cancer patients with stage IIB-IIIB with six series of paclitaxel cisplatin chemotherapy viewed from the perspective of BPJS Kesehatan, hospital was IDR 24,703,470.00, IDR 6,619,204.00, and IDR 9,149,300.00, respectively. Keywords: Cervical Cancer; Chemotherapy; Cost Analysis; Paclitaxel Cisplatin; Societal Perspective
Inflammation Marker and Leukocyte Parameter Ratio on Erythropoiesis Activity of Pediatric Acute Lymphoblastic Leukemia Wande, I Nyoman; Linawati, Ni Made; Dewi, Pande Putu Ayu Patria; Ariawati, Ketut
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 31 No. 3 (2025)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v31i3.2395

Abstract

Acute leukemia is the most common malignancy found in children. A Complete Blood Count (CBC) examination can calculate the lymphocyte-to-leukocyte ratio, neutrophil-to-leukocyte ratio, and neutrophil-to-lymphocyte ratio to monitor the progress of Acute Lymphoblastic Leukemia (ALL). C-reactive protein is a marker of inflammation and can determine disease progression during treatment. The study's analytical design was observational, with a cross-sectional design conducted at the laboratory of the Clinical Pathology Faculty of Medicine, University of Udayana, and Ngoerah Hospital from March to August 2020. The study included 48 subjects, divided into three phases: induction, consolidation, and maintenance, in ALL patients. Specimen collection was collected in 2 tubes. Kolmogorov-Smirnov statistical analysis was used to assess normality, and homogeneity was evaluated with Levene’s test. The difference test was performed using the Kruskal-Wallis test. This study aimed to determine the relationship between parameters was performed with Spearman correlation. This study showed a strong correlation between hemoglobin levels and neutrophil/lymphocyte ratio (r= 0.358, p=0.015), hemoglobin and lymphocyte/leukocyte ratio (r= -0.287, p=0.048), hemoglobin and CRP (r= -0.493, p=0.000). Significant correlation between reticulocyte percentage and neutrophil/lymphocyte ratio (r= 0.505, p=0.000), neutrophil/lymphocyte ratio and CRP (r= -0.870, p=0.000), neutrophil/leukocyte ratio and lymphocyte/leukocyte ratio (r= 0.960, p=0.000). Significant correlations have been found between hemoglobin levels and the neutrophil/lymphocyte ratio (NLR), which is a measure of the lymphocyte/leukocyte ratio (LLeu-ratio), along with CRP. This relationship has been connected to inflammation in ALL patients following chemotherapy. CBC is an easy-to-use test to determine whether inflammation is present in ALL patients following chemotherapy.
Co-Authors A.A. Raka Karsana Anak Agung Made Wijaya Kusuma Anak Agung Ngurah Ketut Putra Widnyana Armand Setiady Liwan Bagus Ngurah Putu Arhana Dewi, N.L.P.R. Dewi, Pande Putu Ayu Patria Djajadiman Gatot Eka Gunawijaya Eko Kristanto Kunta Adjie Endang Windiastuti Gusti Ayu Putu Nilawati H Salim I Gusti Lanang Sidiartha I Gusti Ngurah Made Suwarba I Gusti Ngurah Sanjaya Putra I Made Ady Wirawan I Made Arimbawa I Nyoman Budi Hartawan I Nyoman G. Budiana I Nyoman Wande I Putu Hendri Aryadi I Wayan Bikin Suryawan I Wayan Dharma Artana I Wayan Gustawan I Wayan Suradhipa, I Wayan I. K. Kari Ida Bagus Subanada IGN Sanjaya Inna Narayani Irene Irene Kadek Wini Mardewi Komalasari, K. T. Leni Lukman Luh Putu Rihayani Budi Made Gede Dwi Lingga Utama Made Suadnyani Pasek Mahardika Aprilia Iflahah Manik Trisna Arysanti Ni Kd Rintan Listiani Ekayanti Ni Made Intan Pertiwi Ni Made Linawati Ni Made Rini Suari Ni Putu Siadi Purniti Ni Wayan Kurnia Wati, Ni Wayan Kurnia Niruri, R Niruri, R. NP Veny Kartika Yantie Nyoman Adiputra Paulus Arief Budiman Pertiwi, N.M.I. Putu Dita Arsintha Widma Putu Junara Putra R. Niiruri Rasmaya Niruri Rini Noviyani S. Herawati Sagung Chandra Yowani Sianny Herawati Soetjiningsih Soetjiningsih Soetjiningsih Soetjiningsih Utami, A.A.I.A.Y.T Wega Upendra Sindhughosa Yohannes Adinatha